Business
Mesoblast holds out hope for heart failure drug – Sydney Morning Herald
Shares in the stem cell treatment developer regained some ground after a horror end to 2020.
Shares in stem cell biotech Mesoblast jumped nearly 16 per cent after the company said it would pursue approval for its key heart failure drug in the US despite a clinical trial delivering mixed results.
On Monday the company told investors that additional data from the phase 3 trial of its Revascor product showed a “substantial and durable reductions in heart attacks, strokes and cardiac deaths” in patients with chronic heart failure.
Mesoblast shares bounced after a tough end to 2020, when shares…
-
General22 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
General16 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
General19 hours ago‘Mother’s Day’ solar storm squeezed Earth’s plasmasphere to one-fifth its size
-
General24 hours agoTwo dead after separate road accidents in regional New South Wales